These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 24667968)

  • 61. Activating mutations in ALK provide a therapeutic target in neuroblastoma.
    George RE; Sanda T; Hanna M; Fröhling S; Luther W; Zhang J; Ahn Y; Zhou W; London WB; McGrady P; Xue L; Zozulya S; Gregor VE; Webb TR; Gray NS; Gilliland DG; Diller L; Greulich H; Morris SW; Meyerson M; Look AT
    Nature; 2008 Oct; 455(7215):975-8. PubMed ID: 18923525
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Anaplastic thyroid cancers harbor novel oncogenic mutations of the ALK gene.
    Murugan AK; Xing M
    Cancer Res; 2011 Jul; 71(13):4403-11. PubMed ID: 21596819
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Crizotinib-resistant mutants of EML4-ALK identified through an accelerated mutagenesis screen.
    Zhang S; Wang F; Keats J; Zhu X; Ning Y; Wardwell SD; Moran L; Mohemmad QK; Anjum R; Wang Y; Narasimhan NI; Dalgarno D; Shakespeare WC; Miret JJ; Clackson T; Rivera VM
    Chem Biol Drug Des; 2011 Dec; 78(6):999-1005. PubMed ID: 22034911
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Development of treatment strategies for advanced neuroblastoma.
    Hara J
    Int J Clin Oncol; 2012 Jun; 17(3):196-203. PubMed ID: 22588779
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The targetable kinase PIM1 drives ALK inhibitor resistance in high-risk neuroblastoma independent of MYCN status.
    Trigg RM; Lee LC; Prokoph N; Jahangiri L; Reynolds CP; Amos Burke GA; Probst NA; Han M; Matthews JD; Lim HK; Manners E; Martinez S; Pastor J; Blanco-Aparicio C; Merkel O; de Los Fayos Alonso IG; Kodajova P; Tangermann S; Högler S; Luo J; Kenner L; Turner SD
    Nat Commun; 2019 Nov; 10(1):5428. PubMed ID: 31780656
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Targeting anaplastic lymphoma kinase (ALK) gene alterations in neuroblastoma by using alkylating pyrrole-imidazole polyamides.
    Ota Y; Yoda H; Inoue T; Watanabe T; Shinozaki Y; Takatori A; Nagase H
    PLoS One; 2021; 16(9):e0257718. PubMed ID: 34591871
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Bmi-1 is essential for the tumorigenicity of neuroblastoma cells.
    Cui H; Hu B; Li T; Ma J; Alam G; Gunning WT; Ding HF
    Am J Pathol; 2007 Apr; 170(4):1370-8. PubMed ID: 17392175
    [TBL] [Abstract][Full Text] [Related]  

  • 68. p53 Loss in MYC-Driven Neuroblastoma Leads to Metabolic Adaptations Supporting Radioresistance.
    Yogev O; Barker K; Sikka A; Almeida GS; Hallsworth A; Smith LM; Jamin Y; Ruddle R; Koers A; Webber HT; Raynaud FI; Popov S; Jones C; Petrie K; Robinson SP; Keun HC; Chesler L
    Cancer Res; 2016 May; 76(10):3025-35. PubMed ID: 27197232
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Dual
    Wood AC; Krytska K; Ryles HT; Infarinato NR; Sano R; Hansel TD; Hart LS; King FJ; Smith TR; Ainscow E; Grandinetti KB; Tuntland T; Kim S; Caponigro G; He YQ; Krupa S; Li N; Harris JL; Mossé YP
    Clin Cancer Res; 2017 Jun; 23(11):2856-2868. PubMed ID: 27986745
    [No Abstract]   [Full Text] [Related]  

  • 70. Exploring the structural and functional impact of the ALK F1174L mutation using bioinformatics approach.
    Kumar A; Ramanathan K
    J Mol Model; 2014 Jul; 20(7):2324. PubMed ID: 24952065
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Differential Impact of
    O'Donohue T; Gulati N; Mauguen A; Kushner BH; Shukla N; Rodriguez-Sanchez MI; Bouvier N; Roberts S; Basu E; Cheung NK; Modak S
    JCO Precis Oncol; 2021; 5():. PubMed ID: 34250410
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Chemotherapy-induced apoptosis in a transgenic model of neuroblastoma proceeds through p53 induction.
    Chesler L; Goldenberg DD; Collins R; Grimmer M; Kim GE; Tihan T; Nguyen K; Yakovenko S; Matthay KK; Weiss WA
    Neoplasia; 2008 Nov; 10(11):1268-74. PubMed ID: 18953436
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Genes proximal and distal to MYCN are highly expressed in human neuroblastoma as visualized by comparative expressed sequence hybridization.
    Stock C; Bozsaky E; Watzinger F; Poetschger U; Orel L; Lion T; Kowalska A; Ambros PF
    Am J Pathol; 2008 Jan; 172(1):203-14. PubMed ID: 18165268
    [TBL] [Abstract][Full Text] [Related]  

  • 74. SHP2 Inhibition with TNO155 Increases Efficacy and Overcomes Resistance of ALK Inhibitors in Neuroblastoma.
    Valencia-Sama I; Kee L; Christopher G; Ohh M; Layeghifard M; Shlien A; Hayes MN; Irwin MS
    Cancer Res Commun; 2023 Dec; 3(12):2608-2622. PubMed ID: 38032104
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Two siblings with familial neuroblastoma with distinct clinical phenotypes harboring an ALK germline mutation.
    Kudo K; Ueno H; Sato T; Kubo K; Kanezaki R; Kobayashi A; Kamio T; Sasaki S; Terui K; Kurose A; Yoshida K; Shiozawa Y; Toki T; Ogawa S; Ito E
    Genes Chromosomes Cancer; 2018 Dec; 57(12):665-669. PubMed ID: 30350464
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Platform comparison for evaluation of ALK protein immunohistochemical expression, genomic copy number and hotspot mutation status in neuroblastomas.
    Yan B; Kuick CH; Lim M; Venkataraman K; Tennakoon C; Loh E; Lian D; Leong MY; Lakshmanan M; Tergaonkar V; Sung WK; Soh SY; Chang KT
    PLoS One; 2014; 9(9):e106575. PubMed ID: 25188507
    [TBL] [Abstract][Full Text] [Related]  

  • 77. ALK Protein Expression Is Related to Neuroblastoma Aggressiveness But Is Not Independent Prognostic Factor.
    Lee JW; Park SH; Kang HJ; Park KD; Shin HY; Ahn HS
    Cancer Res Treat; 2018 Apr; 50(2):495-505. PubMed ID: 28546523
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [Ceritinib in the treatment of an adult patient with advanced neuroblastoma positive to the somatic activating mutation of ALK F1174L.].
    Soto Parra HJ; Noto L; Aiello MM
    Recenti Prog Med; 2020 Dec; 111(12):58e-62e. PubMed ID: 33362184
    [TBL] [Abstract][Full Text] [Related]  

  • 79.
    Yogev O; Almeida GS; Barker KT; George SL; Kwok C; Campbell J; Zarowiecki M; Kleftogiannis D; Smith LM; Hallsworth A; Berry P; Möcklinghoff T; Webber HT; Danielson LS; Buttery B; Calton EA; da Costa BM; Poon E; Jamin Y; Lise S; Veal GJ; Sebire N; Robinson SP; Anderson J; Chesler L
    Cancer Res; 2019 Oct; 79(20):5382-5393. PubMed ID: 31405846
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Loss of ALK hotspot mutations in relapsed neuroblastoma.
    Allinson LM; Potts A; Goodman A; Bown N; Bashton M; Thompson D; Basta NO; Gabriel AS; McCorkindale M; Ng A; McNally RJQ; Tweddle DA
    Genes Chromosomes Cancer; 2022 Dec; 61(12):747-753. PubMed ID: 36029175
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.